請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55491
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭鐘金(Chung-Chin Kuo) | |
dc.contributor.author | Ming-Kai Pan | en |
dc.contributor.author | 潘明楷 | zh_TW |
dc.date.accessioned | 2021-06-16T04:05:27Z | - |
dc.date.available | 2016-03-12 | |
dc.date.copyright | 2015-03-12 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-09-16 | |
dc.identifier.citation | 1. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281-285.
2. Olanow CW, Stern MB, and Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1-136. 3. Kravitz AV, Freeze BS, Parker PRL, Kay K, Thwin MT, Deisseroth K, and Kreitzer AC. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622-626. 4. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189-225. 5. Pillai G, Brown NA, McAllister G, Milligan G, and Seabrook GR. Human D2 and D4 dopamine receptors couple through betagamma G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology. 1998;37(8):983-987. 6. Albin RL, Young AB, and Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-375. 7. Benazzouz A, Breit S, Koudsie A, Pollak P, Krack P, and Benabid AL. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002;17 Suppl 3(S145-149. 8. Hollerman JR, and Grace AA. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res. 1992;590(1-2):291-299. 9. Ni ZG, Bouali-Benazzouz R, Gao DM, Benabid AL, and Benazzouz A. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res. 2001;899(1-2):142-147. 10. Vila M, Périer C, Féger J, Yelnik J, Faucheux B, Ruberg M, Raisman-Vozari R, Agid Y, and Hirsch EC. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci. 2000;12(1):337-344. 11. Sharott A, Magill PJ, Harnack D, Kupsch A, Meissner W, and Brown P. Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur J Neurosci. 2005;21(5):1413-1422. 12. Moran RJ, Mallet N, Litvak V, Dolan RJ, Magill PJ, Friston KJ, and Brown P. Alterations in brain connectivity underlying beta oscillations in Parkinsonism. PLoS Comput Biol. 2011;7(8):e1002124. 13. Mallet N, Pogosyan A, Sharott A, Csicsvari J, Bolam JP, Brown P, and Magill PJ. Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci. 2008;28(18):4795-4806. 14. Williams D, Tijssen M, Van Bruggen G, Bosch A, Insola A, Di Lazzaro V, Mazzone P, Oliviero A, Quartarone A, Speelman H, et al. Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans. Brain. 2002;125(Pt 7):1558-1569. 15. Marsden JF, Limousin-Dowsey P, Ashby P, Pollak P, and Brown P. Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson's disease. Brain. 2001;124(Pt 2):378-388. 16. Tai C-H, Yang Y-C, Pan M-K, Huang C-S, and Kuo C-C. Modulation of subthalamic T-type Ca2+ channels remedies locomotor deficits in a rat model of Parkinson disease. The Journal of clinical investigation. 2011;121(8):3289-3305. 17. Tai C-H, Pan M-K, Lin JJ, Huang C-S, Yang Y-C, and Kuo C-C. Subthalamic discharges as a causal determinant of parkinsonian motor deficits. Ann Neurol. 2012;72(3):464-476. 18. Alegre M, and Valencia M. Oscillatory activity in the human basal ganglia: more than just beta, more than just Parkinson's disease. Experimental Neurology. 2013;248(183-186. 19. Bevan MD, Magill PJ, Terman D, Bolam JP, and Wilson CJ. Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci. 2002;25(10):525-531. 20. Eusebio A, Pogosyan A, Wang S, Averbeck B, Gaynor LD, Cantiniaux S, Witjas T, Limousin P, Azulay J-P, and Brown P. Resonance in subthalamo-cortical circuits in Parkinson's disease. Brain. 2009;132(Pt 8):2139-2150. 21. Hammond C, Bergman H, and Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 2007;30(7):357-364. 22. Krause V, Wach C, Südmeyer M, Ferrea S, Schnitzler A, and Pollok B. Cortico-muscular coupling and motor performance are modulated by 20 Hz transcranial alternating current stimulation (tACS) in Parkinson's disease. Front Hum Neurosci. 2013;7(928. 23. Little S, Pogosyan A, Kuhn AA, and Brown P. β band stability over time correlates with Parkinsonian rigidity and bradykinesia. Experimental Neurology. 2012;236(2):383-388. 24. Pogosyan A, Gaynor LD, Eusebio A, and Brown P. Boosting cortical activity at Beta-band frequencies slows movement in humans. Curr Biol. 2009;19(19):1637-1641. 25. Pogosyan A, Yoshida F, Chen CC, Martinez-Torres I, Foltynie T, Limousin P, Zrinzo L, Hariz MI, and Brown P. Parkinsonian impairment correlates with spatially extensive subthalamic oscillatory synchronization. Neuroscience. 2010;171(1):245-257. 26. Tan H, Pogosyan A, Anzak A, Foltynie T, Limousin P, Zrinzo L, Ashkan K, Bogdanovic M, Green AL, Aziz T, et al. Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson's disease. Experimental Neurology. 2013;240(122-129. 27. Chen CC, Litvak V, Gilbertson T, Kühn A, Lu CS, Lee ST, Tsai CH, Tisch S, Limousin P, Hariz M, et al. Excessive synchronization of basal ganglia neurons at 20 Hz slows movement in Parkinson's disease. Experimental Neurology. 2007;205(1):214-221. 28. Fogelson N, Kühn AA, Silberstein P, Limousin PD, Hariz M, Trottenberg T, Kupsch A, and Brown P. Frequency dependent effects of subthalamic nucleus stimulation in Parkinson's disease. Neurosci Lett. 2005;382(1-2):5-9. 29. Cassidy M, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V, and Brown P. Movement-related changes in synchronization in the human basal ganglia. Brain. 2002;125(Pt 6):1235-1246. 30. Doyle LMF, Kühn AA, Hariz M, Kupsch A, Schneider G-H, and Brown P. Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease. Eur J Neurosci. 2005;21(5):1403-1412. 31. Kühn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider G-H, Yarrow K, and Brown P. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain. 2004;127(Pt 4):735-746. 32. Levy R, Ashby P, Hutchison WD, Lang AE, Lozano AM, and Dostrovsky JO. Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain. 2002;125(Pt 6):1196-1209. 33. Loukas C, and Brown P. Online prediction of self-paced hand-movements from subthalamic activity using neural networks in Parkinson's disease. J Neurosci Methods. 2004;137(2):193-205. 34. Priori A, Foffani G, Pesenti A, Bianchi A, Chiesa V, Baselli G, Caputo E, Tamma F, Rampini P, Egidi M, et al. Movement-related modulation of neural activity in human basal ganglia and its L-DOPA dependency: recordings from deep brain stimulation electrodes in patients with Parkinson's disease. Neurol Sci. 2002;23 Suppl 2(S101-102. 35. Williams D, Kühn A, Kupsch A, Tijssen M, van Bruggen G, Speelman H, Hotton G, Loukas C, and Brown P. The relationship between oscillatory activity and motor reaction time in the parkinsonian subthalamic nucleus. Eur J Neurosci. 2005;21(1):249-258. 36. Williams D, Kühn A, Kupsch A, Tijssen M, van Bruggen G, Speelman H, Hotton G, Yarrow K, and Brown P. Behavioural cues are associated with modulations of synchronous oscillations in the human subthalamic nucleus. Brain. 2003;126(Pt 9):1975-1985. 37. Fornaguera J, Huston JP, Carey RJ, and Schwarting RK. Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions. Psychopharmacology (Berl). 1995;119(2):145-154. 38. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, and Montastruc J-L. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226-2231. 39. Nambu A, Tokuno H, and Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002;43(2):111-117. 40. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res. 2004;143(461-466. 41. Nambu A. [Functions of direct, indirect and hyperdirect pathways]. Brain Nerve. 2009;61(4):360-372. 42. Kubota S, and Rubin JE. NMDA-induced burst firing in a model subthalamic nucleus neuron. J Neurophysiol. 2011;106(2):527-537. 43. Gradinaru V, Mogri M, Thompson KR, Henderson JM, and Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324(5925):354-359. 44. Rouzaire-Dubois B, and Scarnati E. Pharmacological study of the cortical-induced excitation of subthalamic nucleus neurons in the rat: evidence for amino acids as putative neurotransmitters. Neuroscience. 1987;21(2):429-440. 45. Maurice N, Deniau JM, Glowinski J, and Thierry AM. Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the corticosubthalamic circuits. J Neurosci. 1998;18(22):9539-9546. 46. Kitai ST, and Deniau JM. Cortical inputs to the subthalamus: intracellular analysis. Brain Res. 1981;214(2):411-415. 47. Fujimoto K, and Kita H. Response characteristics of subthalamic neurons to the stimulation of the sensorimotor cortex in the rat. Brain Res. 1993;609(1-2):185-192. 48. Nakanishi H, Kita H, and Kitai ST. An N-methyl-D-aspartate receptor mediated excitatory postsynaptic potential evoked in subthalamic neurons in an in vitro slice preparation of the rat. Neurosci Lett. 1988;95(1-3):130-136. 49. Nambu A, Tokuno H, Hamada I, Kita H, Imanishi M, Akazawa T, Ikeuchi Y, and Hasegawa N. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol. 2000;84(1):289-300. 50. Flores G, Liang JJ, Sierra A, Martínez-Fong D, Quirion R, Aceves J, and Srivastava LK. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience. 1999;91(2):549-556. 51. Bouthenet ML, Martres MP, Sales N, and Schwartz JC. A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride. Neuroscience. 1987;20(1):117-155. 52. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, and Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991;564(2):203-219. 53. Boyson SJ, McGonigle P, and Molinoff PB. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci. 1986;6(11):3177-3188. 54. Dawson TM, Barone P, Sidhu A, Wamsley JK, and Chase TN. The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neuroscience. 1988;26(1):83-100. 55. Dawson VL, Dawson TM, Filloux FM, and Wamsley JK. Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sci. 1988;42(20):1933-1939. 56. Johnson AE, Coirini H, Kallstrom L, and Wiesel FA. Characterization of dopamine receptor binding sites in the subthalamic nucleus. Neuroreport. 1994;5(14):1836-1838. 57. Kreiss DS, Anderson LA, and Walters JR. Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons. Neuroscience. 1996;72(3):863-876. 58. Mansour A, Meador-Woodruff JH, Zhou Q, Civelli O, Akil H, and Watson SJ. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience. 1992;46(4):959-971. 59. Martres MP, Bouthenet ML, Sales N, Sokoloff P, and Schwartz JC. Widespread distribution of brain dopamine receptors evidenced with [125I]iodosulpride, a highly selective ligand. Science. 1985;228(4700):752-755. 60. Savasta M, Dubois A, and Scatton B. Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res. 1986;375(2):291-301. 61. Ni Z, Bouali-Benazzouz R, Gao D, Benabid AL, and Benazzouz A. Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat. Synapse. 2001;40(2):145-153. 62. Campbell GA, Eckardt MJ, and Weight FF. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. Brain Res. 1985;333(2):261-270. 63. Hassani OK, Francois C, Yelnik J, and Feger J. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res. 1997;749(1):88-94. 64. Meibach RC, and Katzman R. Catecholaminergic innervation of the subthalamic nucleus: evidence for a rostral continuation of the A9 (substantia nigra) dopaminergic cell group. Brain Res. 1979;173(2):364-368. 65. Heida T, Marani E, and Usunoff KG. The subthalamic nucleus part II: modelling and simulation of activity. Advances in anatomy, embryology, and cell biology. 2008;199(1-85,vii. 66. Suri RE, Albani C, and Glattfelder AH. A dynamic model of motor basal ganglia functions. Biol Cybern. 1997;76(6):451-458. 67. Huettner JE, and Bean BP. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(4):1307-1311. 68. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, and Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 1995;34(10):1239-1258. 69. Stukel JM, Parks J, Caplan MR, and Tillery SIH. Temporal and spatial control of neural effects following intracerebral microinfusion. J Drug Target. 2008;16(3):198-205. 70. Wang H, Peca J, Matsuzaki M, Matsuzaki K, Noguchi J, Qiu L, Wang D, Zhang F, Boyden E, Deisseroth K, et al. High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc Natl Acad Sci U S A. 2007;104(19):8143-8148. 71. Arenkiel BR, Peca J, Davison IG, Feliciano C, Deisseroth K, Augustine GJ, Ehlers MD, and Feng G. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. Neuron. 2007;54(2):205-218. 72. Beurrier C, Congar P, Bioulac B, and Hammond C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J Neurosci. 1999;19(2):599-609. 73. Overton PG, and Greenfield SA. Determinants of neuronal firing pattern in the guinea-pig subthalamic nucleus: an in vivo and in vitro comparison. J Neural Transm Park Dis Dement Sect. 1995;10(1):41-54. 74. Surmeier DJ, Mercer JN, and Chan CS. Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway? Current Opinion in Neurobiology. 2005;15(3):312-318. 75. Shen K-Z, and Johnson SW. Chronic dopamine depletion augments the functional expression of K-ATP channels in the rat subthalamic nucleus. Neurosci Lett. 2012;531(2):104-108. 76. Shen K-Z, and Johnson SW. Ca2+ influx through NMDA-gated channels activates ATP-sensitive K+ currents through a nitric oxide-cGMP pathway in subthalamic neurons. J Neurosci. 2010;30(5):1882-1893. 77. Petri D, Pum M, Vesper J, Huston JP, and Schnitzler A. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat. Behav Brain Res. 2013;252(58-67. 78. Moro E, Esselink RJ, Xie J, Hommel M, Benabid AL, and Pollak P. The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology. 2002;59(5):706-713. 79. Perouansky M, and Yaari Y. Kinetic properties of NMDA receptor-mediated synaptic currents in rat hippocampal pyramidal cells versus interneurones. J Physiol (Lond). 1993;465(223-244. 80. Benazzouz A, and Hallett M. Mechanism of action of deep brain stimulation. Neurology. 2000;55(12 Suppl 6):S13-16. 81. Li Q, Ke Y, Chan DCW, Qian Z-M, Yung KKL, Ko H, Arbuthnott GW, and Yung W-H. Therapeutic deep brain stimulation in Parkinsonian rats directly influences motor cortex. Neuron. 2012;76(5):1030-1041. 82. Burbaud P, Bonnet B, Guehl D, Lagueny A, and Bioulac B. Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res. 1998;780(1):102-107. 83. Crossman AR, Sambrook MA, and Jackson A. Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain. 1984;107 ( Pt 2)(579-596. 84. Murer MG, and Pazo JH. Circling behaviour induced by activation of GABAA receptors in the subthalamic nucleus. Neuroreport. 1993;4(11):1219-1222. 85. Scheel-Kruger J, Magelund G, and Olianas M. The role of GABA in the basal ganglia and limbic system for behaviour. Adv Biochem Psychopharmacol. 1981;29(23-36. 86. Bronfeld M, Belelovsky K, Erez Y, Bugaysen J, Korngreen A, and Bar-Gad I. Bicuculline-induced chorea manifests in focal rather than globalized abnormalities in the activation of the external and internal globus pallidus. J Neurophysiol.104(6):3261-3275. 87. Spooren WP, Helfrich SE, and Cools AR. Interactions of the subthalamic nucleus and the subpallidal area in oro-facial dyskinesia: role of GABA and glutamate. Psychopharmacology (Berl). 1995;119(1):20-26. 88. Hubsher G, Haider M, and Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096-1099. 89. Johnson JW, and Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61-67. 90. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci. 2000;20(21):7871-7879. 91. Phillips JM, Lam HA, Ackerson LC, and Maidment NT. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci. 2006;23(1):151-160. 92. Loucif AJC, Woodhall GL, Sehirli US, and Stanford IM. Depolarisation and suppression of burst firing activity in the mouse subthalamic nucleus by dopamine D1/D5 receptor activation of a cyclic-nucleotide gated non-specific cation conductance. Neuropharmacology. 2008;55(1):94-105. 93. Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622. 94. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain. 2014;137(Pt 4):1145-1155. 95. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, and Hallett M. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron. 2010;65(1):135-142. 96. van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TDL, Houle S, Miyasaki JM, Zurowski M, Lang AE, and Strafella AP. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology. 2010;75(19):1711-1716. 97. Tindell AJ, Berridge KC, Zhang J, Peciña S, and Aldridge JW. Ventral pallidal neurons code incentive motivation: amplification by mesolimbic sensitization and amphetamine. Eur J Neurosci. 2005;22(10):2617-2634. 98. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner E-M, Poewe W, Rascol O, Goetz CG, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3(S42-80. 99. Schultz W, Dayan P, and Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-1599. 100. Salamone JD, Correa M, Mingote SM, and Weber SM. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol. 2005;5(1):34-41. 101. Robbins TW, and Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology. 1996;6(2):228-236. 102. Montague PR, Dayan P, and Sejnowski TJ. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J Neurosci. 1996;16(5):1936-1947. 103. Gleichgerrcht E, Ibáñez A, Roca M, Torralva T, and Manes F. Decision-making cognition in neurodegenerative diseases. Nat Rev Neurol. 2010;6(11):611-623. 104. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, and Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci. 1999;877(412-438. 105. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, and Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852-858. 106. Caviness JN. Pathophysiology of Parkinson's disease behavior--a view from the network. Parkinsonism Relat Disord. 2014;20 Suppl 1(S39-43. 107. Callesen MB, Scheel-Krüger J, Kringelbach ML, and Møller A. A systematic review of impulse control disorders in Parkinson's disease. J Parkinsons Dis. 2013;3(2):105-138. 108. Berridge KC, and Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309-369. 109. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology. 2007;191(3):391-431. 110. Avila I, and Lin S-C. Motivational salience signal in the basal forebrain is coupled with faster and more precise decision speed. PLoS Biol. 2014;12(3):e1001811. 111. Cerovic M, d'Isa R, Tonini R, and Brambilla R. Molecular and cellular mechanisms of dopamine-mediated behavioral plasticity in the striatum. Neurobiol Learn Mem. 2013;105(63-80. 112. Wilson CJ, and Bevan MD. Intrinsic dynamics and synaptic inputs control the activity patterns of subthalamic nucleus neurons in health and in Parkinson's disease. Neuroscience. 2011;198(54-68. 113. Ramanathan S, Tkatch T, Atherton JF, Wilson CJ, and Bevan MD. D2-like dopamine receptors modulate SKCa channel function in subthalamic nucleus neurons through inhibition of Cav2.2 channels. J Neurophysiol. 2008;99(2):442-459. 114. Baufreton J, and Bevan MD. D2-like dopamine receptor-mediated modulation of activity-dependent plasticity at GABAergic synapses in the subthalamic nucleus. The Journal of Physiology. 2008;586(8):2121-2142. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55491 | - |
dc.description.abstract | 巴金森氏病是最常見的動作障礙疾病,在症狀學上以動作不能做為主要表現。在病理學上,中腦於黑質緻密部的多巴胺神經元退化是其動作障礙的主因,並伴隨了兩個電生理異常表現:視丘下核過多的叢集式放電,及大腦—視丘下核間的不正常共振。在基底神經核的動作控制理論上,巴金森氏病也是最重要的疾病模式之一。中腦的多巴胺神經元退化,使興奮性的直接路徑受到過度壓制,而抑制性的間接路徑則受到過度活化,進而造成總體性的抑制效果而引發動作困難。雖然以直接—間接路徑為主的病理機轉為現今主流,仍有許多臨床現象及動作實驗結果無法解釋。在大腦—基底神經核的迴路中除了直接及間接路徑,還有一個較少被提及的大腦皮質—視丘下核路徑,或被稱之為「超直接路徑」。此一路徑由大腦直接支配視丘下核而越過了紋狀體—這個多巴胺調控直接及間接路徑的必經之路。然而,超直接路徑和巴金森氏病的關聯性仍屬未知。因此,我博士學程的研究課題即是超直接路徑在巴金森動作障礙的角色。
在以鼠類模式為基礎的實驗中,我們發現阻斷視丘下核的NMDA受體可以成功的治療巴金森的動作困難,並同時矯正兩大電生理異常。相對於NMDA受體,AMPA受體在動作行為或電生理表現上,並沒有顯著的效應。由此可知,經由NMDA受體的傳遞的超直接路徑在巴金森氏病中扮演了關鍵性的角色。在進一步的實驗中我們發現,於大腦刺激超直接路徑,可以在巴金森鼠的視丘下核引發過多的叢集式放電,以及異常的放電時間。這兩個超直接路徑機轉可直接導致巴金森氏病的兩大電生理異常,亦可被NMDA受體抑制劑所矯治。雖然此機轉在巴金森氏病有其必要性,因果關係的建立需要更強的證據。因此,我們進一步利用新興的光遺傳學方法,在沒有多巴胺缺乏的正常鼠上,選擇性的刺激超直接路徑。我們發現,模擬巴金森鼠之放電模式來刺激超直接路徑,可以立刻誘發正常鼠產生巴金森動作障礙。由此可知,依靠NMDA受體的超直接路徑異常,是造成巴金森動作困難的充要條件及核心機轉。為更深入檢驗超直接路徑機轉在巴金森氏病的角色,我們選用MK-801來干預巴金森鼠的行為。MK-801只抑制已開啟的NMDA受體,且結合受體所需時間為超直接路徑傳遞時間的數千倍。依前述的超直接路徑機轉,我們預測MK-801雖亦為NMDA受體抑制劑,但應無療效。實驗結果證實我們的推論,並對超直接路徑調控巴金森動作障礙的細部原理提供了進一步的佐證。 新發現的超直接路徑機轉,並不牽涉到紋狀體及直接-間接路徑的多巴胺調控。因此,了解多巴胺治療在巴金森氏病的原理成為一重要課題。我們進一步發現,多巴胺在巴金森氏病的療效可以歸因於視丘下核的調節。將多巴胺受體的促效劑注入視丘下核,就足以治療巴金森動作障礙而不需矯治紋狀體或直接-間接路徑的多巴胺缺乏。這個結果撼動了多巴胺治療的基礎原理,並提供了新的治療方向及契機。 由於超直接路徑越過了紋狀體,不論是電生理機轉,NMDA受體相關的療效,甚或多巴胺的治療機轉,都不需要紋狀體的直接調控。而中腦於黑質緻密部的多巴胺神經元,主要支配紋狀體及視丘下核。因此,我們進一步解析視丘下核的多巴胺去神經化,是否就足以產生巴金森動作障礙。實驗結果證實,選擇性損害支配視丘下核的多巴胺神經元,並不足使老鼠產生巴金森症狀。因此,紋狀體的多巴胺調控,在巴金森的致症機轉上仍有其角色。 總體而言,這一系統研究得出以下結論:巴金森氏病的動作障礙乃歸因於超直接路徑的異常,而多巴胺治療的原理亦歸因於視丘下核的調控。雖然超直接路徑的異常是巴金森症狀的直接原因及充要條件,紋狀體的多巴胺調節對巴金森的病態變化(即超直接路徑的異常)的成因仍具有關鍵性的角色。 | zh_TW |
dc.description.abstract | Parkinson’s disease (PD) is the most prevalent movement disorder, and the prototypical disease model showing hypokinetic movements. Electrophysiologically, excessive subthalamic bursts and cortico-subthalamic beta synchronization are two specific abnormalities in PD. The symptomatic pathogenesis has been ascribable to the imbalance between direct and indirect pathways in the basal ganglia circuitry. However, there are still electrophysiological and clinical observations remains unexplained. Here we found that inhibition of NMDAergic cortico-subthalamic transmission rescues both motor deficits and electrophysiological abnormalities in 6-OHDA parkinsonian rats. Stimulation of premotor cortex further characterizes that NMDAergic cortico-subthalamic transmission in PD causes excessive burst generation in subthalamic nucleus (STN) and time-locked transmission between cortex and STN, which explain the firing pattern and synchronization-based abnormalities, respectively. Moreover, by mimicking the over-activation and synchronization of cortico-subthalamic transmission with optogenetic stimulation, we can instantaneously and reversibly induce parkinsonian symptoms in normal mice. The results clearly show that deranged NMDAergic cortico-subthalamic transmission is both essential and sufficient, hence causative, for hypokinetic motor deficits. Furthermore, subthalamic microinfusion of apomorphine, a dopaminergic agent commonly used in the treatment of PD, readily remedies parkinsonian motor deficits without correcting the dopaminergic deficiency in striatum. The behavioral results also show that NMDAergic intervention in STN does not cause paradoxical movements, which are widely seen in the standard dopaminergic treatment of PD animals, indicating that we target on the hypokinetic-specific mechanism. We further challenge this new model with MK-801, which is also a NMDA receptor blocker but only work on open channel with binding rate 1,000 times slower than the cortico-subthalamic transmission time. Our model successfully predicts the failure of the electrophysiological and behavioral effects in PD. To further explore the generating mechanism of the cortico-subthalamic derangement, we applied a rat model of subthalamic 6-OHDA microinfusion, which selectively deprived dopaminergic innervation in STN but preserved those in striatum. This manipulation failed to generate parkinsonian behaviors. In conclusion, our results show that deranged cortico-subthalamic transmission is the causative mechanism of parkinsonian motor behaviors. Although striatal dopamine pathology is not the direct pathophysiology of the motor deficits, it may still play some roles, with or without the dopaminergic denervation in STN, in the pathogenesis of cortico-subthalamic mechanism. Our works clearly impact the current concepts of parkinsonian motor control as well as related therapies, and significantly contribute to the revisit of the true essential elements of motor control theory in the basal ganglia circuitry. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T04:05:27Z (GMT). No. of bitstreams: 1 ntu-103-D98441002-1.pdf: 7452215 bytes, checksum: d1b5a4e354bd89e6e046de2a6e7d0a81 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………………………… i
誌謝……………………………………………………………………………………………… ii 中文摘要………………………………………………………………………………………… iii 英文摘要………………………………………………………………………….……………… v 第一章 Introduction ………….………………………………………………………………… 1 1.1 The model of direct and indirect pathways in motor control theory …………………… 2 1.2 The classical model of motor deficits in Parkinson’s disease ………………………… 3 1.3 The electrophysiological manifestations in Parkinson’s disease ……………………… 4 1.4 The unsolved paradox between parkinsonian motor deficits and classic model of motor control theory …………………………………………………………………………… 5 1.5 The role of cortico-subthalamic pathway in the basal ganglia circuitry ………………… 6 1.6 Aim of the study ………………………………………………………………………… 6 第二章 Materials and Methods ………………………………………………………………… 7 2.1 Neurotransmitter receptor modulators ………………………………………………… 8 2.2 Animal materials and preparation of parkinsonian model ………………………… 8 2.3 Implantation of microinfusion cannula ………………………………………………… 9 2.4 Implantation of fiber optic cannula …………………………………………………… 10 2.5 Open-field test of animal behaviors …………………………………………………… 10 2.6 Continuous in vivo single-unit recording ……………………………………………… 11 2.7 Evoked single-unit recording with premotor electrical stimulation …………………… 12 2.8 Implantations of electrodes for local field potentials …………………………………… 13 2.9 Recordings of cortical and subthalamic local field potentials ………………………… 14 2.10 Data processing of continuous and evoked single-unit recordings …………………… 14 2.11 Data processing of local field potentials ……………………………………………… 15 2.12 Statistical Analysis …………………………………………………………………… 16 2.13 Verification of the recording sites and 6-OHDA lesions ……………………………… 16 2.14 Study approval ………………………………………………………………………… 17 第三章 Results…………………………………………………………………………………… 18 3.1 NMDAergic transmission in STN is required for parkinsonian hypokinetic movements 19 3.2 NMDAergic transmission in STN is required for optimized normal motor behaviors … 24 3.3 NMDAergic transmission in STN generates burst firings ……………………………… 26 3.4 NMDAergic cortico-subthalamic transmission generates subthalamic bursts ………… 31 3.5 NMDAergic cortico-subthalamic transmission regulates time-dependent firings in STN 33 3.6 NMDA receptor blocker suppresses cortico-subthalamic synchronization …………… 35 3.7 NMDA receptor blocker suppresses synchronization in situ …………………………… 38 3.8 NMDA receptor pore blocker fails to modulate parkinsonian manifestations ………… 43 3.9 Cortico-subthalamic overactivation triggers parkinsonian hypokinetic movements …… 46 3.10 Dopaminergic denervation in STN is not sufficient for parkinsonian motor deficits… 50 3.11 Conclusion …………………………………………………………………………… 52 第四章 Discussion ……………………………………………………………………………… 54 4.1 Excitatory inputs in the basal ganglia circuitry has an essential role in parkinsonian motor deficits …………………………………………………………………………………… 55 4.2 NMDA receptor generates functional changes in parkinsonian STN …………………… 55 4.3 The basis of beta synchronization and its impact in the therapeutics of deep brain stimulation in PD ………………………………………………………………………… 57 4.4 The therapeutic impact of cortico-subthalamic mechanism in PD ……………………… 58 4.5 The role of striatal dopaminergic denervation in Parkinsonian motor deficits………… 59 4.6 The role of cortico-subthalamic transmission in normal motor processing …………… 60 參考文獻 ………………………………………………………………………………………… 62 附錄 ……………………………………………………………………………………………… 71 Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits. | |
dc.language.iso | en | |
dc.title | 大腦皮質-視丘下核路徑在巴金森動作障礙之角色 | zh_TW |
dc.title | The Role of Cortico-subthalamic Pathway in Parkinsonian Motor Deficits | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 吳瑞美(Ruei-Meei Wu),蔡明正(Ming-Cheng Tai),黃榮棋(Rong-Chi Huang),劉天申(Tian-Shen Liu) | |
dc.subject.keyword | 大腦皮質-視丘下核路徑,超直接路徑,巴金森氏病,動作障礙,動作控制, | zh_TW |
dc.subject.keyword | Cortico-subthalamic pathway,NMDA receptor,Parkinson’s disease,parkinsonian motor deficits,motor control, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-09-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 7.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。